<DOC>
	<DOC>NCT00655512</DOC>
	<brief_summary>to compare the atrophogenic potentials of pimecrolimus 1% cream, hydrocortisonacetat 1% cream, betamethasonvalerat 0,1% cream and clobetasol-17-Propionat 0,05% cream</brief_summary>
	<brief_title>Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound</brief_title>
	<detailed_description />
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>male and female probands age between 1840 years skin healthy skintype IIII according to Fitzpatrick women of childbearing potential without adequate contraception pregnant or breastfeeding genetic defect of epidermal barrier external or systemic treatment with drugs, which probably have an effect to the thickness of skin or to the production of teleangiektasien within the last 6 month before study entry skin disease, which hinder the evaluation with OCT, ultrasound or dermaphot UV treatment within the last 4 weeks before study entry participation to another clinical trial within the last 30 days before study entry allergy against pimecrolimus or hydrocortison or betamethasonvalerat or Clobetasol17propionat severe systemic diseases; ongoing immunosuppressive treatment planned vaccination should realize before study entry or 28 days after end of treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>pimecrolimus</keyword>
	<keyword>hydrocortison</keyword>
	<keyword>betamethasone</keyword>
	<keyword>clobetasol-17-Propionat</keyword>
	<keyword>Optical Coherence Tomography</keyword>
	<keyword>skin healthy probands</keyword>
</DOC>